We are honored to welcome Sander van Deventer, MD, PhD, a distinguished figure in the life sciences industry, as Strategic Advisor at Genewity. His vast experience in drug development and gene therapy will be an asset to our company.

Sander has been instrumental in several landmark developments in the biotech sector. He played a critical role in the development of Remicade, the first commercial monoclonal antibody, and Glybera, the first gene therapy approved in the Western world. As the co-founder and CEO of VectorY, he has been leading efforts to create transformative gene therapies for neurodegenerative diseases​.

‍

Sander’s business acumen is evident from his successful ventures. He co-founded the leading venture capital firm Forbion where he still serves as Operating Partner. He co- founded Amsterdam Molecular Therapeutics, now known as uniQure, where he served in various executive roles including CSO, CMO, and CEO. His leadership at uniQure was pivotal in advancing their hemophilia B and Huntington's disease programs through clinical development.

‍

“Having Sander van Deventer join our advisory board is an extraordinary honor,” says Arno Bisschop, CEO. “His insights based on his track record in strategic leadership and the development of advanced therapies will be invaluable as we push the boundaries of cell and gene therapy.”

‍

Bart Bergstein, CFO: “Having worked closely with Sander before, I can personally attest to his exceptional knowledge and entrepreneurial spirit in bringing new therapies to the market. I am thrilled to reunite with him at Genewity to bring our innovative therapies to the market.”

‍